Jun 24 |
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
|
Jun 21 |
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
|
Jun 4 |
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
Jun 3 |
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
|
May 31 |
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
|
May 30 |
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
|
May 15 |
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
|
May 15 |
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|
May 14 |
US Equity Markets Close Higher Tuesday as Producer Prices Rise
|
May 14 |
Ascendis Pharma says FDA has delayed TransCon PTH review
|